Ascendis Pharma A/S - ADR

NASDAQ:ASND   11:30:09 AM EDT
99.91
-0.23 (-0.23%)
Products

Ascendis Pharma Submits TransCon PTH Drug Application To U.S. FDA

Published: 08/31/2022 12:40 GMT
Ascendis Pharma A/S - ADR (ASND) - Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients With Hypoparathyroidism.
Ascendis Pharma A/s - European Maa on Track for Q4 2022 Submission.
Ascendis Pharma A/s - Expects to Announce Topline Results for Pathway Japan, Phase 3 Trial of Transcon Pth in Japan in Q4.